司库奇尤单抗可能改善银屑病患者的肾功能。
Ixekizumab May Improve Renal Function in Psoriasis.
作者信息
Amoruso Giuseppe Fabrizio, Nisticò Steven Paul, Iannone Luigi, Russo Emilio, Rago Giuseppe, Patruno Cataldo, Bennardo Luigi
机构信息
Unit of Dermatology, Mariano Santo Hospital, 87100 Cosenza, Italy.
Unit of Dermatology, Department of Health Sciences, Magna Graecia University, Viale Europa SNC, 88100 Catanzaro, Italy.
出版信息
Healthcare (Basel). 2021 May 7;9(5):543. doi: 10.3390/healthcare9050543.
BACKGROUND
Psoriasis is a chronic dermatological condition characterized by lesions on extensor surfaces, hands, feet, and genital areas. Chronic renal failure is often associated with metabolic syndrome and inflammatory conditions, such as psoriasis.
CASE REPORT
In this paper, we report a patient with stage-three chronic renal failure that improved his renal condition after treatment with ixekizumab, an anti-IL17A drug used in the treatment of various cutaneous and rheumatological conditions.
CONCLUSIONS
IL17A blockage may help to treat various autoimmune and inflammatory conditions, such as psoriasis, that may lead to renal impairment. Further investigation is necessary in order to prove the effectiveness of this drug in renal conditions.
背景
银屑病是一种慢性皮肤病，其特征为伸侧表面、手部、足部和生殖器区域出现皮损。慢性肾衰竭常与代谢综合征及炎症性疾病相关，如银屑病。
病例报告
在本文中，我们报告了一名三期慢性肾衰竭患者，其在使用用于治疗各种皮肤和风湿性疾病的抗白细胞介素17A（IL17A）药物司库奇尤单抗治疗后，肾脏状况得到改善。
结论
阻断IL17A可能有助于治疗各种自身免疫性和炎症性疾病，如可能导致肾功能损害的银屑病。为证明该药物在肾脏疾病中的有效性，有必要进行进一步研究。
Zotero 插件